Clindamycin

The exact Pfizer strength has current sourced Georgian and EU/EEA human registrations and an accessible current exact SmPC; Dalacin/Cleocin clindamycin capsules also have long regulator experience. Veterinary oral clindamycin capsules are authorised for relevant dog/cat infections, but this human presentation is not the authorised veterinary product and its animal use remains off-label.

Oral clindamycin has applicable canine capsule PK, authorised veterinary infection claims and controlled evidence in susceptible canine pyoderma, with strong activity against many Gram-positive cocci and anaerobes. Current stewardship narrows use to a compatible infection and susceptibility context; inducible MLSB resistance, enterococci and aerobic Gram-negative organisms limit empirical breadth, and source control remains essential.

Vomiting and diarrhoea occur occasionally; dysbiosis, resistant-organism or yeast overgrowth, hypersensitivity and hepatic/renal abnormalities are recognised. The exact human capsule also carries severe antibiotic-associated colitis and oesophageal-injury warnings. Correct hydration/swallowing, course selection and laboratory monitoring in prolonged or organ-impaired cases give a generally usable margin.

A stable immediate-release whole capsule is simple for a dog that can swallow it and whose calculated dose is close to 150 mg. It cannot be divided into validated smaller units; small dogs and many q12h regimens need a lower-strength veterinary capsule, liquid or pharmacy-prepared alternative, and every dose should be followed by food or water.

The exact Pfizer strength has current sourced Georgian and EU/EEA human registrations and an accessible current exact SmPC; Dalacin/Cleocin clindamycin capsules also have long regulator experience. Veterinary oral clindamycin capsules are authorised for relevant dog/cat infections, but this human presentation is not the authorised veterinary product and its animal use remains off-label.

Clindamycin has applicable feline oral PK, authorised veterinary wound/oral infection claims and an established clinical role in compatible toxoplasmosis. Direct feline controlled outcome evidence is limited, toxoplasmosis diagnosis is imperfect, and the drug does not provide broad aerobic Gram-negative coverage; drainage, dental treatment and other source control remain essential.

GI upset and superinfection are recognised, and cats have a specific serious capsule hazard: five reported cats given dry 75 mg clindamycin capsules developed oesophagitis or stricture. A food or water chaser reduces pill retention but does not make these 150/300 mg whole capsules dose-appropriate; prolonged therapy or renal/hepatic disease also needs monitoring.

A 150 mg whole capsule greatly exceeds common single doses for an average cat and the exact label requires swallowing whole; unvalidated powder splitting sacrifices dose accuracy. Cats also need an immediate food or water chaser to reduce oesophageal retention, so a 25 mg veterinary capsule, liquid or pharmacy-compounded patient-specific form is normally preferable.

The exact Pfizer strength has current sourced Georgian and EU/EEA human registrations and an accessible current exact SmPC; Dalacin/Cleocin clindamycin capsules also have long regulator experience. Veterinary oral clindamycin capsules are authorised for relevant dog/cat infections, but this human presentation is not the authorised veterinary product and its animal use remains off-label.

Oral clindamycin has applicable canine capsule PK, authorised veterinary infection claims and controlled evidence in susceptible canine pyoderma, with strong activity against many Gram-positive cocci and anaerobes. Current stewardship narrows use to a compatible infection and susceptibility context; inducible MLSB resistance, enterococci and aerobic Gram-negative organisms limit empirical breadth, and source control remains essential.

Vomiting and diarrhoea occur occasionally; dysbiosis, resistant-organism or yeast overgrowth, hypersensitivity and hepatic/renal abnormalities are recognised. The exact human capsule also carries severe antibiotic-associated colitis and oesophageal-injury warnings. Correct hydration/swallowing, course selection and laboratory monitoring in prolonged or organ-impaired cases give a generally usable margin.

The whole 300 mg capsule can fit some large-dog regimens and reduces pill count at high doses, but cannot be divided into validated smaller units. It is unsuitable for most small/medium dogs and inflexible for dose adjustment; a lower-strength veterinary capsule, liquid or pharmacy-prepared alternative is often needed.

The exact Pfizer strength has current sourced Georgian and EU/EEA human registrations and an accessible current exact SmPC; Dalacin/Cleocin clindamycin capsules also have long regulator experience. Veterinary oral clindamycin capsules are authorised for relevant dog/cat infections, but this human presentation is not the authorised veterinary product and its animal use remains off-label.

Clindamycin has applicable feline oral PK, authorised veterinary wound/oral infection claims and an established clinical role in compatible toxoplasmosis. Direct feline controlled outcome evidence is limited, toxoplasmosis diagnosis is imperfect, and the drug does not provide broad aerobic Gram-negative coverage; drainage, dental treatment and other source control remain essential.

GI upset and superinfection are recognised, and cats have a specific serious capsule hazard: five reported cats given dry 75 mg clindamycin capsules developed oesophagitis or stricture. A food or water chaser reduces pill retention but does not make these 150/300 mg whole capsules dose-appropriate; prolonged therapy or renal/hepatic disease also needs monitoring.

A 300 mg whole capsule is not a realistic dose unit for an average cat and cannot be divided into validated portions under the exact label. Opening and estimating powder is inaccurate, while dry capsules can cause oesophageal injury; a veterinary liquid, 25 mg capsule or pharmacy-compounded patient-specific form should be selected instead.

The exact Pfizer 150 mg/ml 2 ml and 4 ml ampoules have current sourced human registrations in Georgia, EU/EEA, GB and US and a current exact SmPC. Clindamycin has authorised veterinary oral comparators, but neither this human phosphate injection nor its IV/IM route is authorised for dogs or cats.

Two direct canine parenteral PK studies support systemic exposure; 11 mg/kg IV maintained concentrations above reported MICs for staphylococci and many anaerobes over the studied interval. Clinical outcome evidence is mostly from oral veterinary use, so susceptibility, infection site, source control and stewardship remain decisive; aerobic Gram-negative organisms, enterococci and CNS infection are not reliably covered.

The exact solution contains 9 mg/ml benzyl alcohol and requires dilution for IV use, a concentration no higher than 18 mg/ml and an infusion rate no faster than 30 mg/min; rapid or undiluted IV dosing is unsafe. Direct canine studies found IM pain and marked CPK elevation, with one phosphate study concluding IM could not be recommended. GI dysbiosis, hypersensitivity, renal/hepatic abnormalities and neuromuscular blockade remain relevant.

The 2 ml ampoule contains 300 mg and is the less wasteful exact pack for small patients. It is ready for undiluted IM injection, but canine local-tolerance evidence argues against routine IM use. IV dosing needs aseptic withdrawal, compatible diluent, concentration/rate calculation, venous access and monitored infusion; opened single-use remainder is discarded.

The exact Pfizer 150 mg/ml 2 ml and 4 ml ampoules have current sourced human registrations in Georgia, EU/EEA, GB and US and a current exact SmPC. Clindamycin has authorised veterinary oral comparators, but neither this human phosphate injection nor its IV/IM route is authorised for dogs or cats.

Clindamycin has an established feline systemic role in susceptible wounds/oral infections and compatible toxoplasmosis, but direct controlled evidence for this IV/IM human phosphate formulation in cats is absent. Published IV use is largely case-level and cannot establish route-specific benefit; diagnosis, susceptibility and source control remain essential.

The exact solution contains 9 mg/ml benzyl alcohol, and feline safety for repeated exposure to this excipient/formulation is not established. Mandatory IV dilution and rate control, injection-site injury, GI dysbiosis, hypersensitivity and neuromuscular-blockade interactions remain relevant; direct feline IV/IM tolerability data are insufficient, so the safety margin is uncertain.

The 2 ml ampoule contains 300 mg and is the less wasteful exact pack for small patients. It is ready for undiluted IM injection, but canine local-tolerance evidence argues against routine IM use. IV dosing needs aseptic withdrawal, compatible diluent, concentration/rate calculation, venous access and monitored infusion; opened single-use remainder is discarded.

The exact Pfizer 150 mg/ml 2 ml and 4 ml ampoules have current sourced human registrations in Georgia, EU/EEA, GB and US and a current exact SmPC. Clindamycin has authorised veterinary oral comparators, but neither this human phosphate injection nor its IV/IM route is authorised for dogs or cats.

Two direct canine parenteral PK studies support systemic exposure; 11 mg/kg IV maintained concentrations above reported MICs for staphylococci and many anaerobes over the studied interval. Clinical outcome evidence is mostly from oral veterinary use, so susceptibility, infection site, source control and stewardship remain decisive; aerobic Gram-negative organisms, enterococci and CNS infection are not reliably covered.

The exact solution contains 9 mg/ml benzyl alcohol and requires dilution for IV use, a concentration no higher than 18 mg/ml and an infusion rate no faster than 30 mg/min; rapid or undiluted IV dosing is unsafe. Direct canine studies found IM pain and marked CPK elevation, with one phosphate study concluding IM could not be recommended. GI dysbiosis, hypersensitivity, renal/hepatic abnormalities and neuromuscular blockade remain relevant.

The 4 ml ampoule contains 600 mg and can reduce ampoule count for a large dog or high hospital dose, but creates substantial waste for cats and small dogs. IV use requires aseptic dilution, concentration/rate calculation, venous access and monitored infusion; IM delivery of large volumes is painful and poorly supported, and opened remainder is discarded.

The exact Pfizer 150 mg/ml 2 ml and 4 ml ampoules have current sourced human registrations in Georgia, EU/EEA, GB and US and a current exact SmPC. Clindamycin has authorised veterinary oral comparators, but neither this human phosphate injection nor its IV/IM route is authorised for dogs or cats.

Clindamycin has an established feline systemic role in susceptible wounds/oral infections and compatible toxoplasmosis, but direct controlled evidence for this IV/IM human phosphate formulation in cats is absent. Published IV use is largely case-level and cannot establish route-specific benefit; diagnosis, susceptibility and source control remain essential.

The exact solution contains 9 mg/ml benzyl alcohol, and feline safety for repeated exposure to this excipient/formulation is not established. Mandatory IV dilution and rate control, injection-site injury, GI dysbiosis, hypersensitivity and neuromuscular-blockade interactions remain relevant; direct feline IV/IM tolerability data are insufficient, so the safety margin is uncertain.

The 4 ml ampoule contains 600 mg and can reduce ampoule count for a large dog or high hospital dose, but creates substantial waste for cats and small dogs. IV use requires aseptic dilution, concentration/rate calculation, venous access and monitored infusion; IM delivery of large volumes is painful and poorly supported, and opened remainder is discarded.